Overview of Our Integrated Proteomics and Bioinformatics Services Platform The Systems Proteomics Company 2011 March 25.

Slides:



Advertisements
Similar presentations
TWO STEP EQUATIONS 1. SOLVE FOR X 2. DO THE ADDITION STEP FIRST
Advertisements

You have been given a mission and a code. Use the code to complete the mission and you will save the world from obliteration…
Cedars Sinai Medical Center
Advanced Piloting Cruise Plot.
Chapter 1 The Study of Body Function Image PowerPoint
Copyright © 2011, Elsevier Inc. All rights reserved. Chapter 5 Author: Julia Richards and R. Scott Hawley.
1 Copyright © 2010, Elsevier Inc. All rights Reserved Fig 2.1 Chapter 2.
1 Chapter 40 - Physiology and Pathophysiology of Diuretic Action Copyright © 2013 Elsevier Inc. All rights reserved.
By D. Fisher Geometric Transformations. Reflection, Rotation, or Translation 1.
The Drug Discovery Process
Challenges In Progressing Biomarkers To Clinical Use Proteomic Experiences Chris Harbron Technical Lead For High Dimensional Data AstraZeneca FDA Industry.
Business Transaction Management Software for Application Coordination 1 Business Processes and Coordination.
T H O M S O N S C I E N T I F I C Ann Wescott April 8, 2008 Prous Science Update SLA DPHT Spring Meeting 2008.
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
Title Subtitle.
Determine Eligibility Chapter 4. Determine Eligibility 4-2 Objectives Search for Customer on database Enter application signed date and eligibility determination.
0 - 0.
ALGEBRAIC EXPRESSIONS
DIVIDING INTEGERS 1. IF THE SIGNS ARE THE SAME THE ANSWER IS POSITIVE 2. IF THE SIGNS ARE DIFFERENT THE ANSWER IS NEGATIVE.
MULTIPLYING MONOMIALS TIMES POLYNOMIALS (DISTRIBUTIVE PROPERTY)
ADDING INTEGERS 1. POS. + POS. = POS. 2. NEG. + NEG. = NEG. 3. POS. + NEG. OR NEG. + POS. SUBTRACT TAKE SIGN OF BIGGER ABSOLUTE VALUE.
SUBTRACTING INTEGERS 1. CHANGE THE SUBTRACTION SIGN TO ADDITION
MULT. INTEGERS 1. IF THE SIGNS ARE THE SAME THE ANSWER IS POSITIVE 2. IF THE SIGNS ARE DIFFERENT THE ANSWER IS NEGATIVE.
FACTORING ax2 + bx + c Think “unfoil” Work down, Show all steps.
Addition Facts
Year 6 mental test 5 second questions
ZMQS ZMQS
REVIEW: Arthropod ID. 1. Name the subphylum. 2. Name the subphylum. 3. Name the order.
BT Wholesale October Creating your own telephone network WHOLESALE CALLS LINE ASSOCIATED.
ABC Technology Project
1 Undirected Breadth First Search F A BCG DE H 2 F A BCG DE H Queue: A get Undiscovered Fringe Finished Active 0 distance from A visit(A)
© S Haughton more than 3?
VOORBLAD.
Chapter 5 Opener.
1 Breadth First Search s s Undiscovered Discovered Finished Queue: s Top of queue 2 1 Shortest path from s.
Factor P 16 8(8-5ab) 4(d² + 4) 3rs(2r – s) 15cd(1 + 2cd) 8(4a² + 3b²)
Squares and Square Root WALK. Solve each problem REVIEW:
Analysis of the Epidermal Growth Factor Receptor and K-Ras genes in patients with Non-small Cell Lung Cancer H. Mugalaasi1, J. Davies2, L Medley2, D Talbot2,
Lets play bingo!!. Calculate: MEAN Calculate: MEDIAN
Past Tense Probe. Past Tense Probe Past Tense Probe – Practice 1.
Chapter 5 Test Review Sections 5-1 through 5-4.
GG Consulting, LLC I-SUITE. Source: TEA SHARS Frequently asked questions 2.
© ETH Zürich | Genevestigator | This module was contributed by Philip Zimmermann Genevestigator – Module I Overview of Genevestigator.
1 First EMRAS II Technical Meeting IAEA Headquarters, Vienna, 19–23 January 2009.
Addition 1’s to 20.
25 seconds left…...
Equal or Not. Equal or Not
Slippery Slope
Test B, 100 Subtraction Facts
Week 1.
We will resume in: 25 Minutes.
1 Unit 1 Kinematics Chapter 1 Day
PSSA Preparation.
How Cells Obtain Energy from Food
1 BioSystems International Lung Cancer Biomarker Test February 25th
1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.
with an emphasis on DNA microarrays
Probe into Discovery and Translational Service in Creative BioMart
CS 790 – Bioinformatics Introduction and overview.
Finish up array applications Move on to proteomics Protein microarrays.
Overview of The Kinexus Integrated Proteomics and Bioinformatics
Volume 63, Issue 1, Pages (January 2003)
Drug Design and Drug Discovery
Volume 22, Issue 7, Pages (July 2015)
Volume 22, Issue 7, Pages (July 2015)
Identification of NSC as a FADD-kinase inhibitor.
Presentation transcript:

Overview of Our Integrated Proteomics and Bioinformatics Services Platform The Systems Proteomics Company 2011 March 25

2 The Kinexus Discovery Platform MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES IMMUNO- HISTOCHEM GRAPHICS SERVICES We have created a highly integrated platform of unique proteomics and bioinformatics services to identify disease biomarkers and drug targets and to foster signal transduction research Our proteomics services are unmatched by any company for convenience, breadth, accuracy, cost and turn-around time

3 Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES CELL CULTURE 12 cell lines Kinexus offers cell lysates from 16 of the most commonly studied human tumour cell lines prepared according to client specifications for proteomics analysis 16 cell lines

4 Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES CELL CULTURE 12 cell lines 16 cell lines ANTIBODY VALIDATION PROTEIN CHARACTERIZATION >40 monkey, rat + mouse tissues ANIMAL TISSUES Clients can also choose from over 230 pre-made cell and tissue lysates for use in our proteomics services

5 Microarray Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES ANTIBODY MICROARRAYS >650 antibodies >800 antibodies Close up of 1 of 16 grids on a Kinex Antibody Microarray - control (blue) and treated (red) have been overlaid and staggered for comparison.

6 MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES ANTIBODY MICROARRAYS REVERSE MICROARRAYS >650 antibodies >800 antibodies Microarray Services >230 lysates Close up of a section of the Standard Kinex Reverse Lysate Microarray. Custom KRLM chips can also be produced for our clients with their own cell/tissue lysates.

7 MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES ANTIBODY MICROARRAYS REVERSE MICROARRAYS >650 antibodies PROTEIN KINASE MICROARRAYS >230 lysates >800 antibodies Microarray Services ~200 kinases Close up of a section of the Kinex Protein Kinase Microarray. The binding of an ATP analogue to active protein kinase is shown.

8 MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES ANTIBODY MICROARRAYS REVERSE MICROARRAYS >650 antibodies PROTEIN KINASE MICROARRAYS >230 lysates >800 antibodies ~200 kinases PEPTIDE MICROARRAYS Microarray Services ~450 peptides Close up of a section of the Kinex Kinase Substrate Microarray chip. The binding of a phosphate detection dye to phosphorylated peptides is shown.

9 Multi-Immunoblotting Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES PAN-SPECIFIC AB Kinases Phosphatases 2 screens KPKS-1.2 multi-immunoblot showing half of the protein kinases detected with this screen.

Multi-Immunoblotting Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES PAN-SPECIFIC AB PHOSPHO- SPECIFIC AB Kinases Phosphatases Phosphosites 2 screens 4 screens Overlay of two KPSS multi-immunoblots showing the effects of staurosporin on Jurkat T cell phosphorylation. Red bands correspond to increased phosphorylation and blue bands reveal decreases in phosphorylation. 10

11 Multi-Immunoblotting Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES PAN-SPECIFIC AB PHOSPHO- SPECIFIC AB CUSTOM AB Kinases Phosphatases Phosphosites 4 screens 2 screens KCPS antibodies tested on 1 lysate sample KCSS cell/tissue samples tested with up to 3 antibodies

Mass Spectrometry Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES PROTEIN ID Identify cross- reactive proteins PROTEIN PHOSPHORYLATION Identify phospho- sites in a protein PROTEOME PHOSPHORYLATION Track hundreds of phosphosites KINASE SUBSTRATE PROFILING Identify kinase Substrate proteins 12

In Silico Prediction Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES KINASE MATCH PREDICTION Identify kinases for a phosphosite Obtain a specificity matrix for a kinase KINASE SPECIFICITY PREDICTION PHOSPHOPROTEIN MATCH PREDICTION Identify substrates of a kinase Identify kinases for many phosphosites 13

Probe Production Services MASS SPEC SERVICES IN VIVO SERVICES KINETWORKS BLOTTING SERVICES KINEX MICROARRAY SERVICES IN SILICO SERVICES PROBE PRODUCTION SERVICES SYNTHETIC PEPTIDES Soluble peptides Active enzymes and substrates RECOMBINANT PROTEINS PEPTIDE ARRAYS Peptides on macroarrays Peptides on microarrays 14

Antibody-driven Biomarker Discovery PREPARATION DISCOVERY VALIDATION VALIDATION LOCATION CORRELATION 15 In Vivo custom cell culture and treatment Kinex Antibody Microarrays Kinetworks Multi-immunoblotting Kinex Reverse Lysate Microarrays IHC Immunohistochemistry KiNET and SigNET websites

EGF receptor 3D structure with kinase inhibitor drug Tarceva Protein Kinase Drugs More than 30% of world pharmaceutical research is focused on protein kinases Over 400 human diseases linked to defects in kinase signalling 19 drugs approved and > 150 in clinical trials Most kinase inhibitors in clinical development are for cancer treatment 16

17 Kinexus Discovery Platform Assists All Phases of Drug Discovery and Development DRUG ANALYSIS DRUG TARGET DISCOVERY DRUG DISCOVERY DRUG TARGET VALIDATION PRE-CLINICAL VALIDATION CLINICAL VALIDATION BIOMARKER DISCOVERY PROTEIN SCREENING CELL/TISSUE SCREENING HTP COMPOUND SCREENING CELLS MECHANISM ANIMALS TOXICOLOGY HUMAN PHASE I, II + III TRIALS PATIENT SCREENING MASS SPEC IN VIVO MULTI-BLOTMICROARRAYS IN SILICO PROBE PRODUCTION

18 Kinexus Services for Kinase Drug Discovery KINASE DRUG SPECIFICITY DRUG TARGET KINASE DISCOVERY KINASE ASSAY DEVELOPMENT KINASE SUBSTRATE DISCOVERY PROTEIN SCREENING CELL/TISSUE SCREENING HTP COMPOUND SCREENING CELLS MECHANISM Kinex KAM Kinetworks In Silico Prediction KiNET DB SigNET KB In Silico - IKMP Kinex KAM - CKSP Mass Spec - MSKS Kinex KPKM In Silico - IKSP Kinex - KKSM Peptide Production Kinase Testing - IKPT Binding Assays - Kinex - KPKM Activity Assays - KICP

KiNET DATABANK Kinetworks Immunoblotting DataBase First launched in 2006 Features results from >6,000 immunoblots Over 200,000 protein measurements Search by protein, treatment or cell/tissue Over 95% unpublished data Online at KiNET DataBase 19

PhosphoNET KnowledgeBase Free, online access >92,000 confirmed and 560,000 predicted human phosphorylation sites >23,000 human proteins Functional information for ~2% of phosphosites Evolutionary analyses Kinase prediction SigNET KNOWLEDGE- BANK SigNET KnowledgeBank 20 Online at

ADVISORY BOARD Kinexus Bioinformatics Corp. Suite 1, 8755 Ash Street Vancouver, B.C. Canada V6P 6T3 Phone: Facsimile: